Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.

ABSTRACT:

Background

Many patients with moderate to severe Crohn's disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical questions.

Methods

In this retrospective study, we analyzed the treatment outcome in moderate to severe CD patients with a steroid-dependent/refractory disease course started on IFX. Withdrawal of IFX was evaluated in patients with deep remission defined as clinical (Harvey-Bradshaw Index ≤4), biochemical (fecal calprotectin [FC] ≤150 μg/g stool) over a period of 2 years, and endoscopic and histological remission before discontinuation of IFX.

Results

After induction with IFX, clinical remission was observed in 45/109 patients (41.3%) and

SUBMITTER: Kaymak T 

PROVIDER: S-EPMC5988174 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature